PMID- 29382421
OWN - NLM
STAT- MEDLINE
DCOM- 20180809
LR  - 20180809
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 33
IP  - 12
DP  - 2017 Dec
TI  - [The oxLDL/beta2GPI/anti-beta2GPI antibody complex promotes A7r5 chemotaxis, migration 
      and lipid accumulation].
PG  - 1622-1627
AB  - Objective To explore the effect of the oxidized low-density lipoprotein/beta2 
      -glycoprotein I/beta2 glycoprotein I antibody (oxLDL/beta2GPI/beta2GPI-Ab) complex on the 
      migration, chemotaxis and lipid accumulation of rat thoracic aortic smooth muscle 
      A7r5 cell line, and unveil the role of Toll-like receptor 4 (TLR4) pathway during 
      the process. Methods A7r5 cells were cultured in vitro with or without the 
      pretreatment of TAK-242, a TLR4 inhibitor. Then the cells were stimulated by 
      oxLDL, oxLDL/beta2GPI complex, beta2GPI, beta2GPI-Ab, beta2GPI/beta2GPI-Ab complex or 
      oxLDL/beta2GPI/beta2GPI-Ab complex. Total RNA was extracted from the cells and the mRNA 
      levels of monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinase-9 
      (MMP-9) and acetyl-CoA acetyltransferase 1 (ACAT1) were evaluated by real-time 
      quantitative PCR. The cell supernatants were collected, and the protein levels of 
      MCP-1 and MMP-9 were determined by ELISA. The migration of A7r5 was observed 
      through wound-healing test. A7r5 cells pretreated with or without TAK-242 were 
      stimulated by oxLDL or oxLDL/beta2GPI/beta2GPI-Ab complex, and the content of total 
      cholesterol (TC) and free cholesterol (FC) in them were measured by corresponding 
      test kits. Then the level of intracellular cholesterol ester (CE) was calculated. 
      Results The oxLDL/beta2GPI/beta2GPI-Ab complex promoted the migration and cholesterol 
      accumulation, and up-regulated the expressions of MCP-1, MMP-9 and ACAT1 in A7r5 
      cells. In addition, the application of TLR4 inhibitor, TAK-242, suppressed these 
      effects. Conclusion oxLDL/beta2GPI/beta2GPI-Ab complex contributes to the process of 
      atherosclerosis through promoting the migration, chemotaxis and lipid 
      accumulation of a7r5 in a TLR4-dependent manner.
FAU - Ouyang, Hang
AU  - Ouyang H
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Zhou, Hong
AU  - Zhou H
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China. *Corresponding 
      author, E-mail: hongzhou0123@163.com.
FAU - He, Chao
AU  - He C
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Zhang, Guiting
AU  - Zhang G
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Chen, Yudan
AU  - Chen Y
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Wang, Ting
AU  - Wang T
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - School of Medicine, Jiangsu University, Zhenjiang 212013, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Sulfonamides)
RN  - 0 (Tlr4 protein, rat)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate)
RN  - 0 (oxidized low density lipoprotein)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Animals
MH  - Antigen-Antibody Complex/*pharmacology
MH  - Cell Line
MH  - Cell Movement/drug effects
MH  - Chemotaxis/*drug effects
MH  - Lipid Metabolism/*drug effects
MH  - Lipoproteins, LDL/*pharmacology
MH  - Matrix Metalloproteinase 9/genetics
MH  - Myocytes, Smooth Muscle/*drug effects/metabolism
MH  - Rats
MH  - Signal Transduction/physiology
MH  - Sulfonamides/pharmacology
MH  - Toll-Like Receptor 4/physiology
MH  - beta 2-Glycoprotein I/immunology/*pharmacology
EDAT- 2018/02/01 06:00
MHDA- 2018/08/10 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/08/10 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Dec;33(12):1622-1627.